Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”
Polyrizon Ltd. - Ordinary Shares (PLRZ)
Company Research
Source: GlobeNewswire
Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels, today announced the pricing of its underwritten initial public offering of 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share and three warrants to purchase one ordinary share per warrant, with an initial exercise price of $4.38 per share. Aggregate gross proceeds are expected to be $4.2 million, prior to deducting underwriting discounts and offering expenses. In addition, PLRZ has granted Aegis Capital Corp. (“Aegis”) a 45-day option to purchase up to 143,835 additional units,
Read more
Impact Snapshot
Event Time:
PLRZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRZ alerts
High impacting Polyrizon Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PLRZ
News
- Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge PlatformGlobeNewswire
- Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024GlobeNewswire
- Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T PlatformGlobeNewswire
- Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery PlatformGlobeNewswire
- Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical TrialGlobeNewswire
PLRZ
Sec Filings
- 3/13/25 - Form 6-K
- 3/11/25 - Form POS
- 3/11/25 - Form 20-F
- PLRZ's page on the SEC website